Kalaris Therapeutics (KLRS)
Develops TH103 for neovascular and exudative retinal diseases.
$3.76
Pre-market−0.14 (−3.60%)
At close$3.90(−0.50%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions58 holders · as of Mar 31, 2026 | 78.05% | 18.58M shares | |
| Insiders4 holders · as of Jul 27, 2026 | 3.62% | 861.8K shares | |
| Strategic holders1 holder · as of Mar 25, 2025 | 48.09% | 11.45M shares | |
| Adds to | 129.76% |
23.80M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (23.80M in the company's Sep 3, 2026 report, 21.83M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 129.76%; nothing is left for Other.
Institutions13F, as of Mar 31, 2026
58 holders · 18.58M shares · 15 new positions · 31 increased · 7 reduced · 8 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Samsara Biocapital, LLC | 12.95M | 54.39% | 0 | May 15, 2026 |
| RTW Investments, LP | 1.30M | 5.46% | 0 | May 15, 2026 |
| Paradigm Biocapital Advisors LP | 700.0K | 2.94% | 0 | May 15, 2026 |
| Alyeska Investment Group, L.P. | 572.7K | 2.41% | +169.1K | May 15, 2026 |
| Siren, L.L.C. | 435.8K | 1.83% | 0 | May 14, 2026 |
| Ikarian Capital, LLC | 360.0K | 1.51% | 0 | May 15, 2026 |
| Propel Bio Management, LLC | 295.8K | 1.24% | +253.7K | May 14, 2026 |
| Vanguard Capital Management LLC | 255.3K | 1.07% | +255.3Knew | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 20, 2026 | Srinivas Akkarajudirector, 10 percent owner: | Purchase | 244,300 | $4.83 | 2,224,147 |
| Mar 20, 2026 | Brett R. Hagenofficer: Chief Accounting Officer | Sale | 1,915 | $6.72 | 0 |
| Dec 18, 2025 | Srinivas Akkarajudirector, 10 percent owner: | Purchase | 479,847 | $10.42 | 1,979,847 |
CongressHouse and Senate disclosures
Not reported.